EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes

Ester di Giacomo, Veronica Confalonieri, Fabio Tofani, Massimo Clerici

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.43648 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA Network Open, 2024. Verfasst von Ester di Giacomo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mental Health and Addiction, Health Care Trust-IRCCS San Gerardo Monza, Monza, Italy. Hauptthemen laut MEDLINE: Atomoxetine Hydrochloride, Attention Deficit Disorder with Hyperactivity, Methylphenidate. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders, and it afflicts about 7% of young people. As a consequence, many young women might be pregnant while taking medication for ADHD, but data about safety have not yet been strictly examined.

Objective

To examine adverse effects in offspring of mothers receiving treatment with atomoxetine and methylphenidate during pregnancy. Data Sources Electronic databases (PubMed, Embase, and PsycINFO) were searched for articles published through December 31, 2023, with the following search terms: ( atomoxetine OR methylphenidate ) AND ( pregnancy ). Study Selection Observational studies (eg, cohort studies, case-control studies, case-crossover studies, cross-sectional studies, and registry-based studies) that reported offspring outcomes in pregnancy with atomoxetine and/or methylphenidate and in mothers with ADHD but unexposed to ADHD treatment during pregnancy or from the general population were included. Ten studies of 656 records satisfied criteria. Data Extraction and Synthesis Two independent reviewers performed data extraction according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Meta-analyses were conducted based on reported odds ratios (ORs) and corresponding 95% CIs using a linear random effects model. Each study was inversely weighted by the reported variance of the estimators. Risk of publication bias and analysis of heterogeneity through univariate and multivariate metaregressions were also rated. Data were analyzed from January to March 2024. Main Outcomes and Measures Study outcomes included miscarriages and congenital anomalies.

Results

Ten studies involving 16 621 481 pregnant women, 30 830 of them affected by ADHD, were included. Congenital anomalies or miscarriages were not more frequent in offspring of mothers receiving treatment with methylphenidate or atomoxetine during pregnancy compared with unexposed offspring (OR, 1.14; 95% CI, 0.83-1.55; P = .41; I 2 = 8% for congenital anomalies; OR, 1.15; 95% CI, 0.82-1.62, P = .67; I 2 = 0% for miscarriages) or compared with the general population (OR, 1.19; 95% CI, 0.93-1.53; P = .16; I 2 = 74% for congenital anomalies; OR, 0.98; 95% CI, 0.77-1.25; P = .40; I 2 = 0% for miscarriage). Conclusions and Relevance Evidence from this meta-analysis, which involves a substantial sample of pregnant women with and without ADHD, suggests the maintenance of methylphenidate or atomoxetine during pregnancy is safe, given that congenital anomalies and miscarriages did not appear to significantly increase. Further studies are recommended to support and confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityMethylphenidateFemaleHumansPregnancyAdrenergic Uptake InhibitorsCentral Nervous System StimulantsPregnancy ComplicationsPregnancy OutcomePrenatal Exposure Delayed Effects

Substanzen

Adrenergic Uptake InhibitorsAtomoxetine HydrochlorideCentral Nervous System StimulantsMethylphenidate

Autor:innen und Institutionen

  • Department of Mental Health and Addiction, Health Care Trust-IRCCS San Gerardo Monza, Monza, Italy.
  • School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

Zitieren

APA

di Giacomo, E., Confalonieri, V., Tofani, F., & Clerici, M. (2024). Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.43648

Vancouver

di Giacomo E, Confalonieri V, Tofani F, Clerici M. Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.43648

BibTeX
@article{diGiacomo2024,
  author = {di Giacomo, Ester and Confalonieri, Veronica and Tofani, Fabio and Clerici, Massimo},
  title = {Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.43648}
}
Kostenlos starten →